Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com
'"/>




Page: 1 2 3

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in Boston.  The public is welcome to ... the Array BioPharma website.Event: Wells Fargo Securities Healthcare ... September 10, 2015Time:  , 10:20 a.m. Eastern Time ...
(Date:9/2/2015)... 2, 2015 About Chronic Lymphocytic Leukemia ... characterized by increased production of lymphocytes. It has been ... it can spread to other parts of the body. ... of the slow buildup of the cancerous cells. During ... the spleen, liver, and lymph nodes. The course of ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
(Date:9/3/2015)... , ... September 03, 2015 , ... ... for its upcoming virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing ... CVS Health, Express Scripts and Milliman, will discuss how plan sponsors are adopting ...
(Date:9/3/2015)... ... 2015 , ... Hunters Creek Retrievers is again honored to salute ... Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 Kisses from a ... and Christmas with an extra big smile. , This adorable trained Lab Pup ...
(Date:9/3/2015)... ... September 03, 2015 , ... ProScrub is a set ... & forth, flicker, repeat, and custom speed effects without the use of keyframes. ... of effect. ProScrub tools are perfect complements to energetic video productions. ProScrub ...
(Date:9/3/2015)... ... September 03, 2015 , ... A scar is an unavoidable result of incision or ... of the body's ability to heal itself. The appearance of a scar is dependent on ... age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their own over ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic ... , and Amazon and will be released on DVD early next year, ... a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and ...
Breaking Medicine News(10 mins):Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2
... The Danone Baby Nutrition and Medical Nutrition Divisions ... Zoetermeer, the Netherlands, as the winner of their 2008 ... a supplier-of-the-year award and is given for overall performance ... during 2008," said Rafael Fernandez, business unit vice president ...
... FOR IMMEDIATE RELEASE , Improving rural sanitation by ... lives a year worldwide, scientists in Pennsylvania conclude in ... the current edition of ACS, semi-monthly journal Environmental ... Africa and Asia would experience the greatest savings in ...
... implementable technique to avoid reblockage of arteries that have ... developed by researchers led by Prof. Boris Rubinsky of ... is the "gold-standard" treatment for acute myocardial infarction (heart ... blood supply to part of the beating heart, usually ...
... Health Care Reform, Received More Industry Contributions Than ... and pharmaceutical manufacturers contributed $5.5 million to the ... House of Representatives during the last two election ... reform dominated political discourse, according to the nonprofit, ...
... Journal of Radiation Oncology*Biology*Physics Study Finds that ... Image Information for Planning Partial Breast Irradiation ... the February 1st issue of the International ... of 3D ultrasound with the Clarity(TM) Breast ...
... brochures with National Osteoporosis FoundationCHICAGO, March 9 ... by recent news reports about how osteoporosis medications ... brochure to help them separate fact from fiction. ... National Osteoporosis Foundation to create the brochure, "Osteoporosis ...
Cached Medicine News:Health News:Graham Packaging On-Site Plant in Zoetermeer Wins Top Performance Award From The Danone Baby Nutrition and Medical Nutrition Divisions 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 3Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 4Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 5Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 6Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 7Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 8Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 9Health News: Hebrew University scientist develop technique for eliminating reblockage of arteries 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 2Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 3Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 4Health News:Consumer Watchdog: Health Insurers & Drug Companies Contributed $5.5 Million to Top 10 Senate and House Recipients Since 2005 5Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 2Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 3Health News:Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region 4Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 2Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 3
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Rad-9™...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Halogen-free immersion oil based on ester oil....
Medicine Products: